Lantheus Holdings (LNTH)

The company organizes its business around radiopharmaceutical oncology, precision diagnostics, and strategic partnerships. In oncology, Lantheus is best known for imaging agents that help clinicians locate and assess cancer, including prostate cancer diagnostics used with PET imaging. Its portfolio also includes products that support cardiac imaging, ultrasound enhancement, and other diagnostic procedures performed in hospitals and imaging centers.

Radiopharmaceuticals combine radioactive isotopes with targeted compounds that are designed to highlight specific biological processes in the body. This makes Lantheus part of a growing area of medicine in which imaging is used not only to diagnose disease but also to guide treatment decisions and track response over time. The company’s strategy includes internal development, licensing, manufacturing partnerships, and commercialization agreements that broaden its reach across diagnostic and therapeutic-adjacent markets.

Lantheus generates most of its revenue in the United States, where it sells to hospitals, independent imaging centers, and government healthcare facilities. Outside the US, it uses a mix of direct sales, distributors, licensing partners, and regional relationships in markets such as Europe, Canada, Australia, Asia-Pacific, Central America, and South America. Its prospects depend on procedure volumes, adoption of advanced imaging, isotope supply, regulatory approvals, reimbursement, and competition in nuclear medicine.